Kenvue Inc. (KVUE) Monthly Report
Publication Date: September 22, 2024
Company Overview
Kenvue Inc. (KVUE) is a consumer health company based in Skillman, New Jersey, that was established in 2022 as a spinoff from Johnson & Johnson. Operating in the Household & Personal Products industry within the Consumer Defensive sector, Kenvue focuses on three core segments: Self Care, featuring popular brands like Tylenol and Zyrtec; Skin Health and Beauty, encompassing Neutrogena and Aveeno; and Essential Health, which includes products such as Listerine and Band-Aid. KVUE made its public debut in August 2023 and has quickly established a substantial presence in the market, delivering total revenue of approximately $15.48 billion.
Financial Performance & Stock Analysis
Currently, Kenvue’s stock price stands at $23.02, with analysts projecting a target high of $25.00 and a mean target price of $22.15. The data suggests moderate confidence in the stock’s future performance, with a “hold” recommendation prevailing among analysts, who average a score of 2.6. The stock has shown resilience, trading close to its fifty-two week high of $23.55, significantly outperforming its fifty-day moving average of approximately $20.85. Short interest, at 46,465,782 shares (around 2.43% of the float), indicates a cautious market sentiment, while the company’s solid revenue figures affirm a strong operational foundation.
Future Projections & Market Sentiment
Kenvue’s financial profile demonstrates stability, making it an attractive option for cautious investors. With a target high of $25.00 and a low of $18.00, the current market position suggests potential for growth; however, significant upward movement is not anticipated in the immediate future. As the market continues to evolve, Kenvue is expected to navigate fluctuations within this range, encouraging investors to adopt a measured approach while monitoring economic indicators and company performance. Overall, Kenvue Inc. presents a compelling case for long-term investment with prudent expectations.
| Metric | Value |
|---|---|
| Market Cap | $44.1b |
| Total Debt | $8.6b |
| Total Cash | $1.0b |
| Shares Outstanding | 1.9b |
| Float Shares | 1.9b |
Disclaimer:
The information provided in this monthly report is for informational purposes only and should not be construed as financial, investment, or trading advice. AltStation.io does not guarantee the accuracy, completeness, or timeliness of the data and analyses presented. The content is based on publicly available information, and while we strive to ensure its accuracy, errors and omissions may occur.
Investing in stocks, cryptocurrencies, and other financial instruments involves significant risk, including the potential loss of principal. Past performance is not indicative of future results. Readers should conduct their own research and consult with a qualified financial advisor before making any investment decisions. AltStation.io and its affiliates are not responsible for any losses incurred as a result of using this report.
By using this report, you acknowledge that you understand and accept these terms.